Back

Predictors of kidney-related outcomes in chronic heart failure patients with concomitant type 2 diabetes mellitus treated with dapagliflozin

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - diagnostic methods Biomarkers HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Professor Alexander E Berezin

Paracelsus Private Medical University, Salzburg (Austria)

4 More presentations in this session

Presentation thumbnail
Fractional excretion of sodium and its relation to in-hospital morbidity and mortality in patients admitted with acute decompensated heart failure
Doctor K. Iskarous (Liverpool, GB)
Abstract Slides Video
Presentation thumbnail
The prognostic importance of admission uric acid levels among patients with acute heart failure
Doctor F. Bahouth (Nazareth, IL)
Abstract Slides Video
Presentation thumbnail
Cardiac magnetic resonance imaging left ventricular stroke volume assessment accuracy comparison between short axis steady state free precession and flow velocity encoding gradients
Doctor C. Troupis (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Predicting cardiovascular events in out-of-hospital patients presenting with atypical chest pain and complete left bundle branch block: role of cta and echocardiographic global longitudinal strain.
Doctor M. Feola (Mondovi, IT)
Abstract Slides

Access the full session

Session thumbnail
ePosters in chronic heart failure - diagnostic methods

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Low levels of irisin predicted worsening kidney function in dapagliflozin-treated patients with chronic heart failure and concomitant type 2 diabetes mellitus
thumbnail
Congress Presentation
Effects of SGLT-2 inhibitors on erythropoiesis and the associated cardio-renal benefits in patients with chronic heart failure
thumbnail
Congress Presentation
Cardiovascular diseases and type 2 diabetes mellitus: high heart failure risk and low rate contraindications to SGLT2i

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources